Saturday 17 October 2026
Export MDXHF’s income statement to Excel — free account
MedX Health Corp.
MDXHF Healthcare Diagnostics & Research
MedX Health Corp.’s revenue for fiscal 2025 (year ended December 2025) was $338,700.00, down 5.23% from fiscal 2024. In the quarter to June 2026, revenue grew 33.6%, EPS fell 6.06%, free cash flow grew 41.6% and total debt fell 8.75%, each against the same quarter a year earlier.
0.03
0.00
0.00%
Follow MDXHF
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
40.22 | 8.75 | 33.55 | 7.95 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(29.49) | (3.70) | (22.36) | (4.07) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
48.01 | 12.29 | 39.04 | 13.50 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(7.84) | (1.56) | (5.23) | (2.06) | |
EV/FCF |
(3.53) | (0.79) | (2.82) | (1.07) | |
Quick Ratio |
0.06 | 0.01 | 0.02 | 0.01 | |
Current Ratio |
0.10 | 0.04 | 0.04 | 0.02 | |
Net Debt/EBITDA |
(4.65) | (1.32) | (3.28) | (2.64) | |
Debt/Assets |
322.96% | 241.50% | 497.19% | 656.36% | |
Debt/Equity |
(0.40) | (0.17) | (0.32) | (0.30) | |
Asset Turnover |
0.48 | 0.59 | 0.79 | 0.77 | |
Operating CF/Net income |
0.55 | 0.53 | 0.66 | 0.70 | |
Capex/Depreciation |
(27.98) | (0.14) | (31.21) | 0.00 | |
Interest Coverage |
(2.17) | (2.25) | (2.97) | (3.16) | |
Research and Development Expense of Revenue |
92.67% | 90.32% | 79.55% | 187.72% | |
Selling, General and Administrative Expense of Revenue |
584.42% | 728.23% | 470.14% | 877.31% | |
Intangible Assets out of Total Assets |
85.99 | 155.90 | 177.24 | 0.00 | |
Share Based Compensation of Revenue |
42.67% | 121.77% | 8.95% | 257.19% | |
Graham Net Nets |
(0.50) | (2.42) | (0.54) | (2.41) | |
Graham Number |
0.09 | 0.09 | 0.08 | 0.09 | |
Earnings Yield |
(26.80%) | (152.00%) | (34.50%) | (140.00%) | |
Free Cash Flow Yield |
(33.86%) | (178.45%) | (41.33%) | (158.91%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
(0.02) | (0.02) | (0.02) | (0.02) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.02) | (0.02) | (0.02) | (0.02) | |
Free Cash Flow |
(0.77) | (0.80) | (0.95) | (0.81) | |
Working Capital |
(6.37) | (7.00) | (6.00) | (6.71) | |
Capital Expenditures |
(0.26) | 0.00 | (0.36) | — | |
Net Current Asset Value |
(7.50) | (7.18) | (7.08) | (7.92) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
2.68 | 0.02 | 2.79 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.28 | 0.15 | 0.15 | 0.16 | |
Average Payables |
1.94 | 1.75 | 1.89 | 1.79 | |
Average Inventory |
0.29 | 0.20 | 0.19 | 0.20 | |
Average Assets |
0.78 | 0.57 | 0.49 | 0.53 | |
Average Common Equity |
(6.93) | (6.60) | (6.75) | (7.04) |
Columns are period end dates · fundamentals updated 2 Oct 2026